We’re here to help.

An unexpected diagnosis can be an overwhelming experience. Your healthcare team will weigh the risks and benefits of different treatment options and determine the best approach.

If treatment will include VIGADRONE® (vigabatrin) for Oral Solution, your healthcare team will work hard to help ensure you have access. And, they will guide you through the necessary steps to enable you to start VIGADRONE® as quickly as possible:

  1. 1.Enrollment in the Vigabatrin REMS program
  2. 2.Filling out the patient information section of the Prescription Form.

VIGADRONE® has been prescribed, now what?

To help you get started with VIGADRONE® (vigabatrin) for Oral Solution, we have several resources available, including:

Powder for Oral Solution Instructions for Use
An Instructions for Use guide to give you peace of mind with how to administer VIGADRONE® for the first time, or when you get a refill.
Powder for Oral Solution Medication Guide
A Medication Guide for the most important information to know to help answer some of the most common questions about VIGADRONE®.

We know a lot about infantile spasms.

We’ve helped many patients with infantile spasms (IS), a rare seizure type that produces brief, sudden body spasms, which occur in clusters and are associated with developmental delays and other complications, making effective treatment during a critical window of a child’s development imperative.

The possible benefit of treatment with VIGADRONE® is reducing spasm frequency in infants with IS. VIGADRONE® therapy has not been proven to improve an infant’s development.

We’re not alone.

Over many years, as researchers have studied infantile spasms, there has been an ongoing concerted effort to find the cause, and, hopefully a cure.

We’re not there yet, but we’re not giving up.

For some patients, infantile spasms may be related to a different condition, such as tuberous sclerosis complex (TSC). Additional information is available online.

Vigabatrin REMS Program

The U.S. Food and Drug Administration (FDA) has approved a single shared system Risk Evaluation and Mitigation Strategy (REMS) for all vigabatrin products called the Vigabatrin REMS Program. It is required by the FDA to ensure informed risk-benefit decisions before initiating treatment and to ensure appropriate use of vigabatrin while patients are treated.

Visit the Vigabatrin REMS website for instructions and the FDA-mandated REMS forms.